trial

Glucose and Lipid Metabolism on Antipsychotic Medication

NCTId NCT00515723
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 96 (actual)
Sponsored by Washington University School of Medicine
Primary completion 2008-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
96 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2001-09
Primary completion
2008-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
RisperidoneOlanzapineQuetiapineZiprasidone

Sponsors

Washington University School of MedicineLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
John W. Newcomer, MDPrincipal Investigator

Sites

2 total
St Louis, United StatesSt Louis, United States

Facts & assertions

4 sourced
Enrollment
96
Phase
NA
Primary Completion Date
2008-12
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
Olanzapine
drug
Quetiapine
drug
Ziprasidone
drug
lead_sponsor
Washington University School of Medicine
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Hyperglycemia
indication
Type 2 Diabetes Mellitus
indication
Hyperglycemia
indication
investigator
John W. Newcomer, MD
person